logo
  Join        Login             Stock Quote

Eli Lilly (LLY) Guides 2013 Above Street; Reconfirms 2012 Profit View

 January 04, 2013 08:10 AM
 


(By Balaseshan) Eli Lilly & Co. (NYSE: LLY) reconfirmed its fiscal 2012 earnings guidance and introduced its financial outlook for fiscal 2013 that was better than Street's view. The drugmaker expects the growth trend to continue in 2013.

"At Lilly, we continue to implement the three primary elements of our strategy to bridge our current period of patent expirations and return to sustainable growth. We have made substantial progress in recent years and expect 2013 to continue that trend," said John Lechleiter, Lilly's chairman, president and chief executive officer.

Because the enactment of the American Taxpayer Relief Act of 2012 was not completed until 2013, certain provisions of the Act benefiting the company's 2012 federal taxes, including the extension of the R&D tax credit for 2012, cannot be recognized in Eli Lilly's 2012 financial results and instead will be reflected in its 2013 results.

[Related -Is This The Start Of A Correction?]

For the fiscal 2012, the company reconfirmed its earnings per share (EPS) guidance in the range of $3.68 to $3.78 on a reported basis, or $3.30 to $3.40 on a non-GAAP basis, while Street predicts $3.36.

For 2013, the company expects EPS to be in the range of $4.03 to $4.18 on a reported basis, or $3.75 to $3.90 on a non-GAAP basis. The company anticipates 2013 revenue of between $22.6 billion and $23.4 billion. Street analysts predict EPS of $3.71 on revenue of $22.82 billion.

Total operating expenses in 2013 are expected to be flat to slightly decreasing compared to 2012, reflecting continued expense controls and productivity gains. Marketing, selling and administrative expenses are expected of $7.1 billion to $7.4 billion. Research and development expenses are expected in the range of $5.2 billion to $5.5 billion.

[Related -Eli Lilly & Co. (LLY): Breast Cancer Drug Failure A Big Blow Amid Generic Threats]

"We remain on track to meet or exceed our minimum financial performance targets. From now through 2014, on an annual basis we still expect revenue to be at least $20 billion, net income to be at least $3 billion, and operating cash flow to be at least $4 billion," said Derica Rice, Lilly executive vice president, global services and chief financial officer.

LLY closed Thursday's regular session up 0.42% at $49.72. The stock has been trading between $38.30 and $53.99 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.